adr_usa_0433|CALT|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
adr_usa_0433|CALT|1|Calliditas Therapeutics AB Total Current Assets (Quarterly) (USD)|Calliditas Therapeutics AB Cash and Short Term Investments (Quarterly) (USD)|Calliditas Therapeutics AB Inventories (Quarterly) (USD)|Calliditas Therapeutics AB Net PP&E (Quarterly) (USD)|Calliditas Therapeutics AB Goodwill and Intangibles (Quarterly) (USD)|Calliditas Therapeutics AB Total Liabilities (Quarterly) (USD)|Calliditas Therapeutics AB Total Current Liabilities (Quarterly) (USD)|Calliditas Therapeutics AB Total Long Term Liabilities (Quarterly) (USD)|Calliditas Therapeutics AB Total Deposits (Quarterly) (USD)|Calliditas Therapeutics AB Book Value (Quarterly) (USD)|Calliditas Therapeutics AB Retained Earnings (Quarterly) (USD)|Calliditas Therapeutics AB Treasury Stock (Quarterly) (USD)|Calliditas Therapeutics AB EV to Revenues|Calliditas Therapeutics AB EV to Earnings|Calliditas Therapeutics AB EV to Free Cash Flow|Calliditas Therapeutics AB EV to Assets (Quarterly)|Calliditas Therapeutics AB PS Ratio|Calliditas Therapeutics AB PE Ratio|Calliditas Therapeutics AB Price to Book Value|Calliditas Therapeutics AB PEG Ratio|Calliditas Therapeutics AB Debt to Equity Ratio|Calliditas Therapeutics AB Dividend Yield|Calliditas Therapeutics AB Shareholder Yield (TTM)|Calliditas Therapeutics AB Percent of Shares Outstanding Short|Calliditas Therapeutics AB Total Receivables (Quarterly) (USD)|Calliditas Therapeutics AB Total Payables (Quarterly) (USD)|Calliditas Therapeutics AB Total Capital Stock (Quarterly) (USD)|Calliditas Therapeutics AB Return on Invested Capital|Calliditas Therapeutics AB Quality Ratio Score|Calliditas Therapeutics AB Momentum Score|Calliditas Therapeutics AB Beta (1Y)|Calliditas Therapeutics AB Sustainable Growth Rate (TTM)|Calliditas Therapeutics AB Institutional Investor Ownership Percentage|Calliditas Therapeutics AB Average Diluted Shares Outstanding (Quarterly)|Calliditas Therapeutics AB Total Employees (Annual)|Calliditas Therapeutics AB EPS Diluted (Quarterly) (USD)|Calliditas Therapeutics AB SG&A Expense (Quarterly) (USD)|Calliditas Therapeutics AB Shares Outstanding|Calliditas Therapeutics AB Repurchase of Capital Stock (Quarterly) (USD)|Calliditas Therapeutics AB Ordinary Shares Number (Quarterly)|Calliditas Therapeutics AB Payout Ratio|Calliditas Therapeutics AB Quick Ratio (Quarterly)|Calliditas Therapeutics AB Normalized Diluted EPS (Quarterly) (USD)|Calliditas Therapeutics AB Stock Buybacks (Quarterly) (USD)|Calliditas Therapeutics AB Effective Tax Rate (TTM)|Calliditas Therapeutics AB Return on Equity|Calliditas Therapeutics AB Net Income (TTM) (USD)|Calliditas Therapeutics AB Revenue (TTM) (USD)|Calliditas Therapeutics AB Dividend Per Share (Quarterly) (USD)|Calliditas Therapeutics AB Revenue (Quarterly) (USD)|Calliditas Therapeutics AB Gross Profit (Quarterly) (USD)|Calliditas Therapeutics AB Pre-Tax Income (Quarterly) (USD)|Calliditas Therapeutics AB Net Income (Quarterly) (USD)|Calliditas Therapeutics AB Net Interest Income (Quarterly) (USD)|Calliditas Therapeutics AB Price (USD)|Calliditas Therapeutics AB Total Return Price (USD)|Calliditas Therapeutics AB Enterprise Value (USD)|Calliditas Therapeutics AB 30-Day Average Daily Volume|Calliditas Therapeutics AB 1 Year Price Returns (Daily)|Calliditas Therapeutics AB Short Interest|Calliditas Therapeutics AB PE Ratio (Forward)|Calliditas Therapeutics AB PE Ratio (Forward 1y)|Calliditas Therapeutics AB PS Ratio (Forward)|Calliditas Therapeutics AB PS Ratio (Forward 1y)|Calliditas Therapeutics AB Quarterly EPS Estimates (USD)|Calliditas Therapeutics AB Quarterly Revenue Estimates (USD)|Calliditas Therapeutics AB Quarterly EPS Surprise|Calliditas Therapeutics AB Quarterly Revenue Surprise|Calliditas Therapeutics AB Quarterly Actual EPS (USD)|Calliditas Therapeutics AB Quarterly Actual Revenue (USD)|Calliditas Therapeutics AB Revenue Estimates for Current Fiscal Year (USD)|Calliditas Therapeutics AB Revenue Estimates for Next Fiscal Year (USD)|Calliditas Therapeutics AB Price Target (USD)|Calliditas Therapeutics AB Consensus Recommendation|Calliditas Therapeutics AB Price Target Num Estimates|Calliditas Therapeutics AB EPS Estimates for Current Fiscal Year (USD)|Calliditas Therapeutics AB EPS Estimates for Next Fiscal Year (USD)|Calliditas Therapeutics AB Research and Development Expense (Quarterly) (USD)|Calliditas Therapeutics AB Reconciled Depreciation (Quarterly) (USD)|Calliditas Therapeutics AB Non-Operating Interest Expense (Quarterly) (USD)|Calliditas Therapeutics AB Land and Improvements (Quarterly) (USD)|Calliditas Therapeutics AB Buildings and Improvements (Quarterly) (USD)|Calliditas Therapeutics AB Other Properties (Quarterly) (USD)|Calliditas Therapeutics AB Machine, Furniture & Equipment (Quarterly) (USD)||
adr_usa_0433|CALT|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
adr_usa_0433|CALT|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
adr_usa_0433|CALT|5|91.2142857143|91.2142857143||91.2142857143|91.2|91.2142857143|91.2142857143|91.2142857143||91.2142857143|91.2142857143|||91.25|1.44547563805|91.25|||1.44547563805||91.6666666667|1.44547563805|92|15.2564102564|91.375|91.2142857143|91.2142857143|91.6666666667||30.6666666667|30.7142857143|91.6666666667|30.5|91.2941176471|85.4615384615|91.2941176471|91.2941176471|46.36||91.2142857143|91.6666666667|91.6666666667|91.2941176471|91.2941176471|91.2142857143|91.6666666667|91.2142857143|||91.6666666667||91.2941176471|91.2941176471|91.2941176471|1.44547563805|1.44547563805|1.44547563805|1.44527363184|1.43016759777|15.2564102564||1.44117647059|1.44547563805|1.44547563805|91.4|99|91.4||91.4|91.375|17.8064516129|21.3166666667|22.9230769231|12.6808510638|22.9230769231|16.5555555556|18.0606060606|91.3076923077|91.6666666667||||91.2142857143|||
adr_usa_0433|CALT|6|14|14||14|10|14|14|14||14|14|||4|431|4|||431||6|431|2|39|8|14|14|3||6|7|3|14|17|13|17|17|25||14|3|6|17|17|14|3|14|||6||17|17|17|431|431|431|402|179|39||34|431|431|10|12|5||5|8|62|60|26|47|26|36|33|13|3||||14|||
adr_usa_0433|CALT|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
adr_usa_0433|CALT|201703||||||||||||||||||||||||||||||||||33.2323||-0.0397|0.7535||||||-0.0397|||||||||-1.3177|-1.3177|-0.0842|||||||||||||||||||||||||0.0015|0.0932||||||
adr_usa_0433|CALT|201706||||||||||||||||||||||||||||||||||14.6919||-0.1249|1.2119||||||-0.1249|||||||||-1.8298|-1.8298|-0.0709|||||||||||||||||||||||||0.0015|||||||
adr_usa_0433|CALT|201709||||||||||||||||||||||||||||||||||15.2027||-0.1489|1.5407||||||-0.1489|||||||||-2.2615|-2.2615|-0.1114|||||||||||||||||||||||||0.0015|||||||
adr_usa_0433|CALT|201712|7.5558|7.0132||0.0193||3.5599|3.5599|||4.0569|-39.181|||||||||||||||1.6733|0.0816|||||||16.5491||-0.3125|6.5796|||33.2323|||-0.3125|-7.5982|||-10.2814|||||-4.8724|-4.8724|0.0043|||||||||||||||||||||||||0.0016||||0.0994|||
adr_usa_0433|CALT|201803|6.7806|6.3645||0.0174||3.848|3.848|||2.9909|-43.1644|||||||||||||||1.0309|0.08|||||||16.673||-0.2826|0.9217|||33.2323|||-0.2826||||-13.6823|||||-4.7186|-4.7186|0.0025||||||||||||||||||||||||3.8296||||||||
adr_usa_0433|CALT|201806|7.3292|1.8849||0.0146||6.5697|6.5697|||0.8118|-42.069|||||||||||||||0.6578|0.1472|||||||16.855|10|-0.1248|0.9887|16.6162||33.2323|||-0.1248||||-13.9533|||||-2.1008|-2.1008|0.0025||||||||||||||||||||||||1.1553||||||||
adr_usa_0433|CALT|201809|77.3556|77.1866||0.0134||3.1809|3.1809|||74.2265|-46.2915|||||||||||||||2.171|0.1585|||||||37.157|10|-0.1017|0.8159|17.6012||35.2023|||-0.1017||||-15.2028|||||-3.511|-3.511|-0.0145||||||||||||||||||||||||2.6894||||||||
adr_usa_0433|CALT|201812|72.1559|71.9561||0.0119||3.3677|3.3677|||68.8381|-50.7251|||||||||||||||2.5215|0.1568|||||||35.85|10|-0.1337|0.8629|17.6012||35.2023|||-0.1337||||-15.2185|||||-4.8881|-4.8881|0.0095||||||||||||||||||||||||3.7771|||||0.0905|||
adr_usa_0433|CALT|201903|65.0398|64.2205||0.0421||3.1837|3.1837|||61.9348|-53.5971|||||||||||||||2.2384|0.1515|||||||35.2023|13|-0.1321|1.0698|17.6012||35.2023|||-0.1321||||-15.1448|||||-4.6449|-4.6449|0.0183||||||||||||||||||||||||3.3552||||||||
adr_usa_0433|CALT|201906|75.1394|57.7106||0.7998||5.1201|4.594|0.5261||71.1073|-44.7729|||||||||||||||3.5046|0.1519|||||||17.7185|14|0.4976|2.0113|17.6012||35.2023||12.5623|0.4976||||-4.2384|||14.6369||8.8056|8.8056|-0.2349|||||||||||||||||9.9712|||||||3.3024||||||||
adr_usa_0433|CALT|201909|83.4576|82.2964||0.6846|1.6126|3.1565|2.7216|0.435||82.7964|-47.5388|||||||||||||||1.5273|0.1582|||||||19.2967|14|-0.2713|1.0741|19.3538||38.7076||30.2387|-0.2713|-21.9423|||-5.9584|||||-5.231|-5.231|0.2607|||||||||||||||||14.4348|0.7755||||||4.8186|||||0.6846|||
adr_usa_0433|CALT|201912|87.8718|80.6386||0.6488|1.7193|6.1135|5.7113|0.4023||84.3338|-52.2326||||||||||||||4.9853|2.6176|0.1657|||||||19.3635|14|-0.1292|2.4779|19.3538||38.7076||14.9921|-0.1292|-0.3231|-0.2316||-3.4711|||4.8523||-2.3928|-2.4008|0.0159||||||||||||||||4.8181|19.7032|||||||4.3443|||||0.6503|||
adr_usa_0433|CALT|202003|75.8693|72.6629||0.5502|1.6023|5.9573|5.6991|0.2581||72.258|-55.0332|||||||||||||||2.8287|0.1544|-7.0234||||-7.3193||33.2323|17|-0.3432|1.8727|19.3538||38.7076||12.7498|-0.3432||-0.2201|-7.3193|-5.4519|||0.0493||-6.6217|-6.6256|0.8994||||||||||||||||0.0483||||||||5.6264|||||0.5502|||
adr_usa_0433|CALT|202006|157.011|156.5534||0.5229|1.7232|6.6282|6.3843|0.2439||152.8579|-65.7697|||-19.3936|-81.7896|2.5051|||3.6379||||-19.4066|0.0158||3.1663|0.2057|-22.2306||||-22.2306||20.4578|30|-0.3103|1.9444|23.9692||47.9384||24.5215|-0.3103|-85.6521|-0.0918|-22.2306|-20.6013|||||-6.3369|-6.3438|0.5486|23.2|23.2|399.5321|20804.1333||3798|||16321.4445|24.6751|-0.3||42.3533||-0.1729||0.0489|25.3471|36|1|3|-1.19|-0.235|5.0053|||||0.5229||22.85|22.71
adr_usa_0433|CALT|202009|158.1341|155.8026||0.4721|1.792|7.0709|6.7402|0.3307||153.5628|-83.7895|||-14.3242|-16.9204|2.7609|||3.9026||||-16.8554|0.1636||2.2165|0.2229|-28.3627||||-28.3627|33.4485|24.8755|34|-0.6258|4.6355|24.9708||49.9416||23.1155|-0.6258|-15.039|-0.0903|-28.3627|-30.9613|||||-15.5819|-15.591|-3.7334|24|24|443.4966|52531.4333||40860|||17589.7946|26.5926|-0.26||-23.1154||-0.3201||0.0301|24.8074|37.25|1|4|-1.1767|-0.6827|7.3296|||||0.4721||23.34|36.65
adr_usa_0433|CALT|202012|126.6182|121.6667||0.6603|56.3412|30.5478|12.898|17.6498||147.8227|-112.1771|||-14.953|-21.4215|3.9325|||5.6792||||-11.5979|0.018||6.6365|0.244|-39.2433||||-39.6027|31.0851|24.9986|23|-0.7932|7.4293|24.9708||49.9416||9.433|-0.7932|3.3244|-0.0827|-39.6027|-48.3814|||0.0465||-20.1515|-19.821|-4.3417|33.62|33.62|723.4457|10899.7333||4484|||37.2518|13.6682|-0.45||9.1067||-0.409|0.0481|0.0349|85.8027|49.6|1|5|-1.1767|-0.3123|8.6052|||||0.6665||27.01|28.07
adr_usa_0433|CALT|202103|104.1387|99.4907||0.6744|53.9403|29.1988|13.4449|15.7539||125.6433|-119.54|||-12.2579|-12.3954|3.2237|||5.4784|||||0.0918||6.614|0.2292||||||29.0809|24.9708|46|-0.5995|7.0199|24.9708||49.9416|||-0.5995||1.8428||-56.7388|||||-16.2632|-14.983|1.7445|27.565|27.565|593.0546|13897.9||22932|||30.5427|11.2065|-0.4453|0.0088|-35.1941|-100|-0.6021||4.9082|82.6008|50|1.2|5|-1.7575|-0.5757|10.7578|||||0.6744||29.6|29.6
adr_usa_0433|CALT|202106|86.4747|83.2725||1.0375|56.5058|30.6241|14.3298|16.2943||110.1027|-141.5376|||-13.5584|-11.5749|3.5658|||6.6791|||||0.1809||6.9575|0.2346|||4|2.6074||24.1173|24.9708|54|-0.7614|10.0375|26.1708||49.9416|||-0.7614||1.8653||-69.4106|||||-19.6548|-19.0157|-0.6917|29.45|29.45|655.9753|11952.9333|26.9397|45175|||32.6313|11.9729|-0.4813||-51.0918||-0.7272||1.2308|71.5923|51.2|1.2|5|-1.6904|-0.596|8.9249|||||1.0375||29.05|28.18
adr_usa_0433|CALT|202109|||||||||||||||-8.5827||||5.139|||||0.1583||||||4|4.1549||22.215||||||||||||||||||||||21.62|21.62|486.3979|44037.4|-9.9167|41425|||25.1067|9.212|-0.5733||104.125||0.0237|22.3766|0.3617|70.3223|51.6|1.2|5|-1.7544|-0.5557||||||||16.32|18.39
adr_usa_0433|CALT|202112|||||||||||||||-10.0327||||5.8853|||||0.2247||||||2|1.478||22.3198||||||||||||||||||||||24.76|24.76|568.5742|333520.1|-26.3534|58818||17.1083|10.5499|2.9728|-0.6567||||||22.3092|53.9615|63.2|1.2|5|-1.4205|-1.6865||||||||21.21|19.12
adr_usa_0433|CALT|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.36|5.0947||||||||||||||||||||
adr_usa_0433|CALT|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.3|11.3974||||||||||||||||||||
adr_usa_0433|CALT|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.26|17.8572||||||||||||||||||||
adr_usa_0433|CALT|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.18|23.8603||||||||||||||||||||